Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2020 | Patient advocates for clinical trials

Rena Buckstein • 5 Mar 2020
MDS 2020
Myelodysplastic Syndromes

Rena Buckstein, MD, FRCPC, Odette Cancer Research Program, Sunnybrook Research Institute, Toronto, Canada, discusses having more inclusive clinical trial criteria, and the need to encourage patients to become advocates for clinical trials. This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.

More from Rena Buckstein

2:21
Unmet needs in LR-MDS: RBC transfusion-dependence
Rena Buckstein • 10 Dec 2023
0:47
Screening for CHIP to detect potential TMNs in cancer treatment
Rena Buckstein • 10 Dec 2023
1:18
How our expanding knowledge of pre-malignant conditions may impact clinical decision-making
Rena Buckstein • 10 Dec 2023
3:24
The impact of CHIP on clinical outcomes in older patients with lymphoma undergoing chemotherapy
Rena Buckstein • 10 Dec 2023

Related Videos

2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals